News

The U.S. Food and Drug Administration (FDA) granted the first coronary stent indication for use in patients experiencing an acute myocardial infarction (AMI), or heart attack. The Boston...

February 20, 2012 —Medtronic announced U.S. Food and Drug Administration (FDA) approval of the Resolute Integrity drug-eluting stent (DES)...

February 1, 2012 — Boston Scientific announced the first patient use and European market launch of the Promus Element Plus everolimus-eluting coronary stent system. The first patient implant in...

January 23, 2012 – Boston Scientific Corp. said the U.S. District Court for the District of New Jersey has found all the asserted patents for a coronary stent in a lawsuit brought by Johnson...

January 9, 2012 – A registry that includes every patient in Sweden having percutaneous coronary intervention (PCI) found use of newer generation drug-eluting stents (DES) is associated with lower...

Abbott announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe evaluating the safety and performance of the novel Esprit drug-eluting bioresorbable vascular scaffold (...

Boston Scientific recently announced U.S. Food and Drug Administration (FDA) approval for the Promus Element Plus everolimus-eluting platinum chromium coronary stent system, the company's next-...

December 9, 2011 — Abbott announced Thursday the initiation of ABSORB II, the first randomized, controlled, multi-center clinical trial evaluating the safety, efficacy and performance of the...

November 21, 2011 — Micell Technologies Inc. announced the release of preliminary data from the first-in-human clinical study of the MiStent Sirolimus Drug Eluting Coronary Stent System (MiStent...

November 15, 2011 – The risk of late stent thrombosis (ST) in the first generation of drug-eluting stents continues for up to seven years after implantation, and certain...

November 15, 2011 – A clinical trial that compared the use of drug-eluting balloons (DEB) and bare metal stents (BMS) to both bare metal stents alone and drug-eluting...

November 15, 2011 — Results of ADAPT-DES (Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents) were presented at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT)...

November 15, 2011 — Researchers have found polymer-free amphilimus-eluting stents in de novo coronary artery lesions showed a significantly lower in-stent late loss at six months compared...

November 15, 2011 — A new clinical trial is testing the efficacy of rotational atherectomy (or rotablation, a process of drilling through plaque deposits) prior to implantation of a drug-eluting...

November 15, 2011 — A clinical trial has shown a drug-eluting stent (DES) with a bioabsorbable polymer has comparable outcomes to a DES with a durable polymer. Results of the EVOLVE clinical trial...

November 14, 2011 – OrbusNeich announced the introduction of the Combo dual therapy stent during a breakfast symposium chaired by Martin B. Leon, M.D., professor of medicine and director of the...

November 14, 2011 – The TWENTE clinical trial, which compared Resolute versus Xience V drug-eluting stents in a real-world population established non-inferiority between the two stents as measured...

November 11, 2011 – Boston Scientific reported results from the EVOLVE first human use trial demonstrating the non-inferiority of the Synergy everolimus-eluting stent system compared to the Promus...

November 11, 2011 – Biosensors International Group announced two-year results from the BioFreedom first-in-human trial, which showed similar clinical outcomes between BioFreedom, a polymer-free,...

November 9, 2011 — Currently under review by the U.S. Food and Drug Administration (FDA), the Resolute drug-eluting stent (DES) from Medtronic Inc. continues to demonstrate consistently positive...